Cabergoline for preventing ovarian hyperstimulation syndrome.

@article{Tang2012CabergolineFP,
  title={Cabergoline for preventing ovarian hyperstimulation syndrome.},
  author={Huilin Tang and Tamara Hunter and Yongfang Hu and Suo-di Zhai and Xiaoyan Sheng and Roger Hart},
  journal={The Cochrane database of systematic reviews},
  year={2012},
  volume={2},
  pages={CD008605}
}
BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a complication resulting from administration of human chorionic gonadotrophin (hCG) in assisted reproduction technology (ART) treatment. Most case are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles. Recently, the dopamine agonist cabergoline has been introduced as a secondary prevention intervention for OHSS in women at high risk of OHSS who are undergoing ART treatment. OBJECTIVES To… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…